The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies

Background: Due to the lack of comprehensive evidence based on prospective studies, the efficacy and safety of Janus Kinase (JAK) inhibitors (including tofacitinib, ruxolitinib, baricitinib, ritlecitinib and brepocitinib) for alopecia areata (AA) are yet to be proved. Methods: The systematic review...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Diqin, Fan, Huaying, Chen, Min, Xia, Lin, Wang, Simin, Dong, Wenliang, Wang, Qian, Niu, Suping, Rao, Huiying, Chen, Liming, Nie, Xiaoyan, Fang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449963/
https://www.ncbi.nlm.nih.gov/pubmed/36091777
http://dx.doi.org/10.3389/fphar.2022.950450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449963/
https://www.ncbi.nlm.nih.gov/pubmed/36091777
http://dx.doi.org/10.3389/fphar.2022.950450

Ejemplares similares